Probabilistic risk prediction models and diagnostic prediction for lung cancer screening
Aim 1. To develop probabilistic inference methods for calculating risk over time via a continuous time belief network (CTBN) derived from the full spectrum of observational lung cancer screening data
Aim 2. To determine phenotypic signatures that predict lung cancer and lung cancer biology in screening populations with indeterminate nodules.
Aim 3. To inform lung cancer screening decisions at the population and the individual level through a partially observable Markov decision process (POMDP).
Denise Aberle, MD
William Hsu, PhD
-
Generalizability and Transportability of the National Lung Screening Trial Data: Extending Trial Results to Different Populations.
Inoue K, Hsu W, Arah OA, Prosper AE, Aberle DR, Bui AAT
Cancer Epidemiol Biomarkers Prev. 2021 Sep 20 PUBMED -
Association of Inclusion of More Black Individuals in Lung Cancer Screening With Reduced Mortality.
Prosper AE, Inoue K, Brown K, Bui AAT, Aberle D, Hsu W
JAMA Netw Open. 2021 Aug 2; Volume 4 (Issue 8): Pages e2119629 PUBMED -
Using Sequential Decision Making to Improve Lung Cancer Screening Performance.
Petousis P, Winter A, Speier W, Aberle DR, Hsu W, Bui AAT
IEEE Access. 2019; Volume 7: Pages 119403-119419 PUBMED -
External validation and recalibration of the Brock model to predict probability of cancer in pulmonary nodules using NLST data.
Winter A, Aberle DR, Hsu W
Thorax. 2019 Jun; Volume 74 (Issue 6): Pages 551-563 PUBMED -
Prediction of lung cancer incidence on the low-dose computed tomography arm of the National Lung Screening Trial: A dynamic Bayesian network.
Petousis P, Han SX, Aberle D, Bui AA
Artif Intell Med. 2016 Sep; Volume 72: Pages 42-55 PUBMED